A two-step purification platform for efficient removal of Fab-related impurities: A case study for Ranibizumab

A two-step purification platform for efficient removal of Fab-related impurities: A case study for Ranibizumab

Antibodies (mAbs) and antibody fragments (Fabs) constitute one of the largest and most rapidly expanding groups of protein pharmaceuticals. In particular, antibody fragments have certain advantages over mAbs in some therapeutic settings. However, due to their greater chemical diversity, they are mor...

Full description

Bibliographic Details
Main Authors: Ozge Tatli, Yagmur Oz, Baran Dingiloglu, Duygu Yalcinkaya, Ezgi Basturk, Melis Korkmaz, Latif Akbulut, Derya Hatipoglu, Cansin Kirmacoglu, Buse Akgun, Kubra Turk, Orkun Pinar, Berna Sariyar Akbulut, Zeynep Atabay, Eda Tahir Turanli, Dilek Kazan, Gizem Dinler Doganay
Format: Article
Language:English
Published: Elsevier 2023-11-01
Series:Heliyon
Subjects:
Antibody fragment
Pharmaceutical purification
Biosimilar production
Liquid chromatography
Mass spectrometry
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844023082099

Internet

http://www.sciencedirect.com/science/article/pii/S2405844023082099

Similar Items